Wednesday, July 9, 2025 7/9/2025

Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer

Award Number: R01CA158881
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2011
PERIOD OF PERFORMANCE END DATE: 12/31/2016

Group Awards By:

View Award Description

Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer - DESCRIPTION (provided by applicant): During treatment recurrent cancers build up multidrug resistance to conventional and novel chemotherapeutic agents representing a formidable challenge in clinical cancer therapy, especially for the effective treatment of gynecological malignancies. This R01 proposal describes a targeted-, combination imaging agent and therapeutic nanoemulsion, designated NMI-500, designed to provide timely diagnostic information on where the co-deliver treatment is accumulating and provide clinicians the quantitative insight to adjust treatment schedules in light of this new information. A team of investigators from two commercial and two academic organizations will collaborate to develop this clinically translatable strategy, initially addressing recurrent multidrug resistant phenotype. NMI-500 uses folate to specifically target docetaxel (DTX), and gadolinium (Gd) an MR imaging agent to localized disease as well as distal metastases. NMI-500's targeting moiety folate is known to improve uptake by tumors expressing folate receptor alpha (FR-a). FR- a, largely absent from normal tissue, has been shown to be over expressed on >80% of recurring ovarian tumors. In breast cancer high FR-an expression has been linked to poor clinical outcomes. The imaging component of NMI-500 will be achieved with the MRI contrast agent Gd, which has been shown to enhance contrast efficiency when conjugated to a nanoemulsion.1 Specific aims will assess and validate the imaging, targeting, efficacy and pharmacokinetics of the combination imaging/chemotherapeutic product, NMI-500.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2015	NEMUCORE MEDICAL INNOVATIONS, INC.	33 KIRKLAND CIR	WELLESLEY	MA	02481	NORFOLK	USA	Cancer Detection and Diagnosis Research	000	5	11/8/2016	NON-COMPETING CONTINUATION	$0
2017	2015	NEMUCORE MEDICAL INNOVATIONS, INC.	33 KIRKLAND CIR	WELLESLEY	MA	02481	NORFOLK	USA	Cancer Detection and Diagnosis Research	001	5	7/17/2017	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2015 ( Subtotal = $523,530 )
2015	2015	NEMUCORE MEDICAL INNOVATIONS INC	33 KIRKLAND CIRCLE	WELLESLEY	MA	02481	NORFOLK	USA	Cancer Detection and Diagnosis Research	000	5	3/25/2015	NON-COMPETING CONTINUATION	$523,530
														Subtotal = $523,530

Issue Date FY: 2014 ( Subtotal = $665,610 )
2014	2014	NEMUCORE MEDICAL INNOVATIONS INC	33 KIRKLAND CIRCLE	WELLESLEY	MA	02481	NORFOLK	USA	Cancer Detection and Diagnosis Research	000	4	4/14/2014	NON-COMPETING CONTINUATION	$665,610
														Subtotal = $665,610

Issue Date FY: 2013 ( Subtotal = $596,489 )
2013	2013	NEMUCORE MEDICAL INNOVATIONS INC	33 KIRKLAND CIRCLE	WELLESLEY	MA	02481	NORFOLK	USA	Cancer Detection and Diagnosis Research	000	3	3/7/2013	NON-COMPETING CONTINUATION	$285,553
2013	2013	NEMUCORE MEDICAL INNOVATIONS INC	33 KIRKLAND CIRCLE	WELLESLEY	MA	02481	NORFOLK	USA	Cancer Detection and Diagnosis Research	001	3	6/28/2013	NON-COMPETING CONTINUATION	$310,936
														Subtotal = $596,489

Issue Date FY: 2012 ( Subtotal = $540,181 )
2012	2012	NEMUCORE MEDICAL INNOVATIONS INC	33 KIRKLAND CIRCLE	WELLESLEY	MA	02481	NORFOLK	USA	Cancer Detection and Diagnosis Research	000	2	3/29/2012	NON-COMPETING CONTINUATION	$540,181
														Subtotal = $540,181

Issue Date FY: 2011 ( Subtotal = $568,797 )
2011	2011	NEMUCORE MEDICAL INNOVATIONS INC	33 KIRKLAND CIRCLE	WELLESLEY	MA	02481	NORFOLK	USA	Cancer Detection and Diagnosis Research	000	1	3/28/2011	NEW	$568,797
														Subtotal = $568,797

Grand Total All Awards = $2,894,607

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer

Award Number: R01CA158881

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2011

PERIOD OF PERFORMANCE END DATE: 12/31/2016

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer